1. Home
  2. IMUX vs ARCT Comparison

IMUX vs ARCT Comparison

Compare IMUX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

BUY

Current Price

$6.97

Market Cap

155.8M

Sector

Health Care

ML Signal

BUY

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

SELL

Current Price

$10.35

Market Cap

369.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IMUX
ARCT
Founded
2016
2013
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
369.5M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
IMUX
ARCT
Price
$6.97
$10.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
13
Target Price
★ $43.09
$23.80
AVG Volume (30 Days)
417.3K
★ 736.3K
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.00
20.00
EPS
N/A
★ N/A
Revenue
N/A
★ $82,031,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$64.21
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.51
$5.50
52 Week High
$17.43
$24.14

Technical Indicators

Market Signals
Indicator
IMUX
ARCT
Relative Strength Index (RSI) 28.28 36.07
Support Level $0.83 $6.53
Resistance Level $8.60 $17.85
Average True Range (ATR) 0.69 1.11
MACD 0.04 -0.42
Stochastic Oscillator 17.84 4.67

Price Performance

Historical Comparison
IMUX
ARCT

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Share on Social Networks: